Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma
International Journal of Biological Sciences · 2024 · 20 (9) · 3269-3284
DOI: 10.7150/ijbs.96031 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Ming-Hao Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Quinolines, Liver Neoplasms, Ubiquitin Thiolesterase. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Lenvatinib is the most common multitarget receptor tyrosine kinase inhibitor for the treatment of advanced hepatocellular carcinoma (HCC). Acquired resistance to lenvatinib is one of the major factors leading to the failure of HCC treatment, but the underlying mechanism has not been fully characterized.
Methods
We established lenvatinib-resistant cell lines, cell-derived xenografts (CDXs) and patient-derived xenografts (PDXs) and obtained lenvatinib-resistant HCC tumor tissues for further study.
Results
We found that ubiquitin-specific protease 14 (USP14) was significantly increased in lenvatinib-resistant HCC cells and tumors. Silencing USP14 significantly attenuated lenvatinib resistance in vitro and in vivo. Mechanistically, USP14 directly interacts with and stabilizes calcium- and integrin-binding protein 1 (CIB1) by reversing K48-linked proteolytic ubiquitination at K24, thus facilitating the P21-activated kinase 1 (PAK1)-ERK1/2 signaling axis. Moreover, in vivo adeno-associated virus 9 mediated transduction of CIB1 promoted lenvatinib resistance in PDXs, whereas CIB1 knockdown resensitized the response of PDXs to lenvatinib.
Conclusions
These findings provide new insights into the role of CIB1/PAK1-ERK1/2 signaling in lenvatinib resistance in HCC. Targeting CIB1 and its pathways may be a novel pharmaceutical intervention for the treatment of lenvatinib-resistant HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
- Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou, 225009, China.
- Department of Digestive Medicine, Wuwei People's Hospital, Gansu, 733000, China.
- Department of CT/MRI Center, Wuwei People's Hospital, Gansu, 733000, China.
- Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, 200032, China.
Zitieren
APA
Xu, M. H., Zheng, Y. M., Liang, B. G., Xu, W. X., Cao, J., Wang, P., Dong, Z. Y., Zhou, C. H., Sun, H. C., Ren, N., Ke, A. W., & Shen, Y. H. (2024). Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma. International Journal of Biological Sciences, 20(9), 3269-3284. https://doi.org/10.7150/ijbs.96031
Vancouver
Xu MH, Zheng YM, Liang BG, Xu WX, Cao J, Wang P, et al. Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma. International Journal of Biological Sciences. 2024;20(9):3269-3284. doi:10.7150/ijbs.96031
BibTeX
@article{Xu2024,
author = {Xu, Ming-Hao and Zheng, Yi-Min and Liang, Bu-Gang and Xu, Wen-Xin and Cao, Jun and Wang, Pei and Dong, Zi-Ying and Zhou, Chen-Hao and Sun, Hui-Chuan and Ren, Ning and Ke, Ai-Wu and Shen, Ying-Hao},
title = {Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma},
journal = {International Journal of Biological Sciences},
year = {2024},
volume = {20},
number = {9},
pages = {3269--3284},
doi = {10.7150/ijbs.96031}
}
EUVIMED